Overview

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Status:
Completed

Trial end date:
2019-06-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

AstraZeneca

Treatments:

Carboplatin
Cisplatin
Pemetrexed